An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1

Study identifier:D1346R00002

ClinicalTrials.gov identifier:NCT03259633

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1 with inoperable, progressive/symptomatic plexiform neurofibromas (PN)

Medical condition

NF type1 with inoperable Plexiform Neurofibromas

Phase

N/A

Healthy volunteers

Study drug

Selumetinib

Sex

All

Actual Enrollment

100

Study type

Expanded Access

Age

2 Years - 130 Years

Date

Study Start Date: -

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: -

Verification:

Verified 01 Apr 2020 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Inclusion Criteria

1. Diagnosis of neurofibromatosis type 1 (NF1) and have inoperable, progressive/symptomatic plexiform neurofibromas (PN)
2. Presence of inoperable PN , defined as a PN that cannot be surgically completely removed without risk for substantial morbidity
3. Patients aged ≥2 with onset of disease before they were 18 years and a BSA ≥ 0.55 m2 who are able to swallow whole capsules. (approx. length 15.4 mm, diameter 5.4 mm). A swallow test must be performed before requesting drug
4. Normal cardiac function defined as normal ejection fraction (ECHO, MUGA or cardiac MRI) as per institutional normal and absence of prior heart disease
5. Adequate blood pressure as defined in line with local practice.
6. The patient has exhausted all available approved therapies as appropriate for NF1 with inoperable progressive/symptomatic PN
7. Provision of a signed informed consent prior to any protocol specific procedures. Patients already receiving selumetinib through single patient access who enroll in this protocol must be reconsented and sign the consent form for this intermediate access protocol.
8. For female patients of childbearing potential, have evidence of a post-menopausal status, or a negative urinary or serum pregnancy test.

Exclusion Criteria

1. Unresolved chronic toxicity ≥ CTCAE Grade 2 from previous therapy
2. Patients eligible for any ongoing clinical trials with selumetinib in the indication in question
3. Ophthalmological conditions: Current or past history of retinal pigment epithelial detachment (RPED)/central serous retinopathy (CSR) or retinal vein occlusion Intraocular pressure (IOP) should not be > 21 mmHg for adults or outside the range of normal for children or uncontrolled glaucoma (irrespective of IOP)
4. Male or female patients of reproductive potential and, as judged by the investigator, are not employing an effective method of birth control.
5. Female patients who are breast-feeding.
6. Have evidence of any other significant clinical disorder or laboratory finding that, as judged by the treating physician, makes it undesirable for the patient to participate in the study.
7. Have any evidence of a severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease, active infection (including hepatitis B, hepatitis C, HIV), active bleeding diatheses or renal transplant
8. Have refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease), or significant bowel resection that would adversely affect the absorption / bioavailability of the orally administered study medication

No locations available

Arms	Assigned Interventions

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]

Contact Backup

Medicine Access Clinigen Group